MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide and induces its fibrillization

Ce Zhang1, Yonggang Liu, Jonathan Gilthorpe

  • 1Department of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden. phyzce@nus.edu.sg

Plos One
|March 30, 2012
PubMed

Insights

Inflammation protein S100A9 binds to amyloid-beta (Aβ) peptides, promoting the formation of Alzheimer's disease (AD) amyloid plaques. This interaction may represent a protective brain response by reducing S100A9 toxicity.

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Local inflammation is increasingly implicated in Alzheimer's disease (AD) pathology.
  • The precise mechanisms linking inflammation to AD pathogenesis remain unclear.

Purpose of the Study:

  • To investigate the interaction between the pro-inflammatory protein S100A9 and amyloid-beta (Aβ) peptides.
  • To elucidate the role of S100A9 in the formation of amyloid structures and its impact on cytotoxicity in the context of AD.

Main Methods:

  • Biochemical assays to assess the interaction between S100A9 and Aβ1-40.
  • Analysis of fibrillar structure formation.
  • Cytotoxicity assays to evaluate the impact of the interaction on cell viability.

Main Results:

  • The pro-inflammatory protein S100A9 directly interacts with the Aβ1-40 peptide.
  • This interaction promotes the formation of fibrillar β-amyloid structures.
  • Binding of S100A9 to Aβ1-40 amyloid structures reduces S100A9-mediated cytotoxicity.

Conclusions:

  • Secretion of S100A9 during inflammation contributes to the formation of amyloid plaques in the brain.
  • Amyloid plaque formation, in part mediated by S100A9, may serve as a protective mechanism by sequestering toxic S100A9 species in Alzheimer's disease patients.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...